A New Approach to Evidence in Cardiology

I am in Berlin at the European Heart Rhythm Society meeting. Sadly, this meeting conflicts with the American College of Cardiology meeting in Atlanta.

ACC has produced a bunch of trials worthy of consideration. Since I have duties here at EHRA, I will defer this Monday’s Study of the Week to my friend Vinay Prasad who has an incredible video appraising the REDUCE-AMI study.

I see REDUCE-AMI as one of the most important trials of the modern era—because it tests not using an established therapy. In this case, beta-blockers in patients with recent MI.

I have just sent in a formal appraisal of this trial for editorial review at TheHeart.org | Medscape Cardiology. Until that comes out, please do listen to Vinay.

As you listen, think about a piece of advice I give to trainees.

I often say that the challenge of future cardiologists will not be having a therapy to use, but whether they ought to use it.

Future trials, I think, will increasingly need to study not doing things that we used to do.

Here is Vinay